Hyloris P-006 Project (NDA) – Oral mucositis

HYLORIS P-006 Project

HYL-P-006 is an oral rinse solution of an active substance with free radical scavenger capacities. It is administered in prevention or alleviation of oral mucositis in patients receiving radiotherapy with or without chemotherapy.


Oral Mucositis pathway

Adapted from Sonis, ST J Support Oncol 2004;2 (Suppl 3) 3-8

Oral Mucositis

Oral mucositis occurs as a nonspecific effect of chemotherapy and radiation therapy on the basal epithelium of the mouth. The signs and the symptoms of mucositis generally occur about 5 to 7 days after chemotherapy or almost at any time during radiation therapy. Patients with oral mucositis experience pain, local and systemic infections, and decrease in the ability to eat and speak.

Comments are closed